HMGB1 and glioblastoma: Together, our data provide compelling evidence that HMGB1, released from GBM tumors treated with Ad-Flt3L and Ad-TK in vivo, elicits TLR2 signaling that results in recruitment of BMDC into the tumor mass, with concomitant induction of antitumor specific T cell clonal expansion, long-term survival, and immunological memory.